CLINICAL_TRIALS
trial_result
· 2022-03-03
Clinical Trial Update: Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma [Phase 2]
Summary
Phase 2 study of zanubrutinib in marginal zone lymphoma has completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: BeiGene | Conditions: Marginal Zone Lymphoma, MZL | Phase 2 | Status: COMPLETED | Results posted: 2022-03-03